Virios posts FY2022 net loss $12.2M; cash $7.0M; FDA meeting on IMC-1 Phase 3 in March

Dogwood Therapeutics, Inc.

Net loss Q4 2022 $2.0M ($0.11/share) vs $4.5M in Q4 2021; FY2022 net loss $12.2M ($1.11) vs $16.0M in FY2021.
Cash $7.0M at Dec 31, 2022; expects funding through mid-2024 for current ops but needs additional funds for IMC-1 FM trials.
End-of-Phase 2 meeting with FDA in March 2023 to discuss IMC-1 progression into Phase 3 development.
Patient enrollment complete for exploratory Long-COVID study; top-line results expected mid-2023.
R&D expenses decreased to $1.3M in Q4 2022 vs $2.9M in Q4 2021; FY2022 R&D $8.1M vs $10.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.